Severe acute liver injury associated with lumiracoxib

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 1102-1105

  Pillans, Peter I ^a   Ghiculescu, Razvan A ^a   Lampe, Guy ^a   Wilson, Robert ^a   Wong, Richard ^a   Macdonald, Graeme A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Liver failure; Liver transplantation; Lumiracoxib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARDIOLIPIN ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G ANTIBODY; LA ANTIBODY; LUMIRACOXIB; RO ANTIBODY;

ABNORMAL FECES; ABNORMAL LABORATORY RESULT; ABNORMAL URINE COMPOSITION; ACUTE LIVER INJURY; ADULT; ANTIBODY DETECTION; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 84861468156     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07036.x     Document Type: Article

References (12)

1. Sgro C, Clinard F, Ouazir K etal. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
2. Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1997; 40: 201-8.
3. Lee WM. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003; 349: 474-85.
4. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol. Drug Saf. 2006; 15: 213-20.
5. Fontana RJ, McCashland TM, Brenner KG etal. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl. Surg. 1999; 5: 480-4.
6. st edition. MIMS Australia, CMP Medica Australia, C&C Offset Printing. P5-560. 2007.
7. Withdrawal of lumiracoxib in Australia. Aust. Adv. Drug React. Bull. 2008; 27: 6-7.
8. O'Connor N, Dargan PI, Jones AL. Hepatocellular injury from non-steroidal anti-inflammatory drugs. Q. J. Med. 2003; 96: 787-91.
9. Martini E, Abuaf N, Cavalli F etal. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662-6.
10. Zimmerman HJ, Lewis JH, Ishak KG etal. Ticrynafen-associated hepatic injury. Analysis of 340 cases. Hepatology 1984; 4: 315-23.
11. Manns MP, Obermeyer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26: 1054-66.
12. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N. Engl. J. Med. 2006; 354: 731-9.